In our study, the prevalence of KRAS mutation in melanomas of the female genital tract was notably higher than melanomas of other sites, whereas the prevalence of NRAS mutation in melanomas of the female genital tract was notably lower compared with the prevalence in melanomas arising in nasal cavity, where mutation rates of up to 45%. This evidence concerns the gene NRAS and melanoma.